IL13RA2 and glioblastoma: This trivalent CAR T cell demonstrated improved anti-tumor activity and survival in GBM patient derived xenografts compared to biCAR (IL13Rα2, andEphA2) and single IL13Rα2 CAR T cells, while lower T cell doses were required to control tumor growth.